Evelo Therapeutics is dedicated to transforming cancer therapy through a deep understanding of the cancer microbiome. Evelo is discovering and developing Oncobiotic™ therapies, novel treatments designed to attack cancer by disrupting the microbial environment which supports tumors and protects them from the body's immune system. Evelo's platform disrupts the tumor microenvironment at the metabolic and stromal levels and provides next-generation, microbiome-based immunotherapeutics. Founded at Flagship VentureLabs, Evelo is the first microbiome company focused on cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/04/15 | $35,000,000 |
Flagship Ventures | undisclosed |
